Your browser is no longer supported. Please, upgrade your browser.
Settings
CTLT Catalent, Inc. daily Stock Chart
CTLT [NYSE]
Catalent, Inc.
IndexS&P 500 P/E84.47 EPS (ttm)1.09 Insider Own0.40% Shs Outstand164.51M Perf Week-0.22%
Market Cap15.13B Forward P/E32.99 EPS next Y2.80 Insider Trans-27.63% Shs Float163.22M Perf Month8.50%
Income173.00M PEG7.28 EPS next Q0.38 Inst Own99.09% Short Float0.98% Perf Quarter10.70%
Sales3.09B P/S4.89 EPS this Y20.60% Inst Trans1.46% Short Ratio1.11 Perf Half Y57.56%
Book/sh18.55 P/B4.98 EPS next Y17.05% ROA2.50% Target Price102.30 Perf Year90.89%
Cash/sh5.82 P/C15.88 EPS next 5Y11.60% ROE8.20% 52W Range31.04 - 96.38 Perf YTD64.14%
Dividend- P/FCF- EPS past 5Y-8.30% ROI5.70% 52W High-4.17% Beta1.61
Dividend %- Quick Ratio2.20 Sales past 5Y11.10% Gross Margin31.80% 52W Low197.55% ATR2.38
Employees13900 Current Ratio2.60 Sales Q/Q30.60% Oper. Margin12.20% RSI (14)57.54 Volatility2.53% 2.63%
OptionableYes Debt/Eq1.04 EPS Q/Q72.70% Profit Margin5.60% Rel Volume0.31 Prev Close92.41
ShortableYes LT Debt/Eq1.02 EarningsNov 03 BMO Payout0.00% Avg Volume1.44M Price92.36
Recom1.80 SMA203.14% SMA505.22% SMA20029.88% Volume342,915 Change-0.05%
Jun-25-20Initiated Argus Buy $100
Apr-21-20Initiated RBC Capital Mkts Outperform $65
Mar-02-20Initiated Deutsche Bank Hold
Oct-17-19Resumed Stephens Overweight $56
Aug-28-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jun-21-19Upgrade Jefferies Hold → Buy $50 → $62
Apr-16-19Upgrade UBS Neutral → Buy $43 → $54
Nov-07-18Upgrade First Analysis Sec Neutral → Outperform $47 → $43
Oct-09-18Initiated UBS Neutral
Mar-28-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Mar-21-18Upgrade Raymond James Mkt Perform → Outperform
Feb-06-18Downgrade Stephens Overweight → Equal-Weight
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-17Initiated Needham Hold
Sep-08-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Dec-01-16Initiated Goldman Neutral
Oct-20-16Initiated KeyBanc Capital Mkts Overweight $29
Jun-21-16Upgrade Wells Fargo Market Perform → Outperform
Jun-20-16Upgrade BofA/Merrill Neutral → Buy
May-05-16Downgrade BofA/Merrill Buy → Neutral
Oct-22-20 09:00AM  
Oct-16-20 09:00AM  
Oct-13-20 08:44AM  
08:40AM  
Oct-01-20 07:55AM  
Sep-14-20 09:34AM  
Sep-10-20 09:22AM  
Sep-09-20 12:44PM  
10:14AM  
Sep-08-20 06:28PM  
04:54PM  
04:24PM  
11:20AM  
08:59AM  
08:39AM  
08:39AM  
08:39AM  
08:38AM  
Sep-04-20 07:16PM  
06:11PM  
06:02PM  
Sep-03-20 08:00AM  
Sep-01-20 09:57AM  
09:12AM  
08:32AM  
Aug-31-20 04:35PM  
03:00PM  
01:00PM  
11:19AM  
08:45AM  
07:47AM  
07:15AM  
Aug-24-20 12:30PM  
10:18AM  
08:00AM  
Jul-31-20 12:09PM  
08:00AM  
Jul-30-20 08:13AM  
Jul-12-20 08:54PM  
Jul-10-20 02:06PM  
Jul-09-20 03:55PM  
Jul-05-20 09:07AM  
Jul-01-20 12:01PM  
Jun-26-20 10:35AM  
09:29AM  
08:26AM  
Jun-25-20 02:08PM  
01:09PM  
12:52PM  
11:43AM  
10:43AM  
09:11AM  
08:06AM  
07:46AM  
07:30AM  
07:14AM  
07:02AM  
Jun-16-20 12:06PM  
Jun-15-20 01:45PM  
07:30AM  
Jun-11-20 08:31AM  
Jun-10-20 04:07PM  
Jun-08-20 01:05AM  
Jun-01-20 11:11AM  
May-28-20 04:16PM  
May-27-20 11:22AM  
May-22-20 02:32AM  
May-21-20 12:00AM  
May-14-20 11:51AM  
May-13-20 12:25PM  
May-12-20 09:04AM  
May-09-20 01:23PM  
May-08-20 06:55PM  
04:05PM  
May-06-20 07:40AM  
May-05-20 03:31PM  
09:15AM  
07:28AM  
May-04-20 08:46AM  
08:39AM  
May-03-20 09:23AM  
Apr-30-20 04:30PM  
11:40AM  
Apr-29-20 02:02PM  
08:00AM  
Apr-28-20 12:34PM  
Apr-15-20 04:05PM  
06:49AM  
Apr-13-20 07:44PM  
Mar-23-20 12:12AM  
Mar-17-20 07:07AM  
06:48AM  
Mar-09-20 06:45PM  
Mar-06-20 11:57AM  
Feb-28-20 04:32PM  
Feb-20-20 01:04PM  
Feb-19-20 04:16PM  
07:21AM  
02:55AM  
Feb-18-20 04:05PM  
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; and a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fasman Steven LSVP & General CounselOct 14Option Exercise26.1815,025393,42687,460Oct 16 06:13 PM
Fasman Steven LSVP & General CounselOct 14Sale93.095,510512,93475,921Oct 16 06:13 PM
Schmidt Kay ASVP, Technical OperationsOct 14Sale93.152,985278,04515,764Oct 16 06:13 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Oct 12Sale94.991,680159,58317,202Oct 13 08:24 AM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Option Exercise30.8439,3421,213,36477,960Oct 09 03:24 PM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Sale91.5015,9281,457,41238,618Oct 09 03:24 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Option Exercise36.027,347264,63926,249Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Option Exercise29.90138,1354,130,817404,337Oct 05 07:55 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Sale85.484,359372,60816,690Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Sale86.01182,23115,673,809173,618Oct 05 07:55 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Sep 02Sale89.502,250201,37818,882Sep 08 01:21 PM
LUCIER GREGORY TDirectorJul 30Sale90.0924,0002,162,16016,921Aug 03 12:02 PM
Gunther ScottSVP, Quality & Reg. AffairsJun 29Sale72.002,824203,31813,365Jul 01 06:15 PM
Gennadios AristipposPresident Softgel & Oral TechJun 25Option Exercise27.9722,255622,54159,736Jun 29 06:54 PM
Gennadios AristipposPresident Softgel & Oral TechJun 25Sale73.008,325607,72544,520Jun 29 06:54 PM
LUCIER GREGORY TDirectorFeb 13Buy59.712,000119,42040,921Feb 14 02:43 PM
Maselli AlessandroPresident & COODec 16Sale53.187,268386,51212,802Dec 18 08:51 AM
Pravda RicardoSVP & Chief HR OfficerNov 26Sale52.732,612137,71810,846Nov 27 11:36 AM
Gennadios AristipposPresident Softgel & Oral TechNov 25Option Exercise18.35123,8802,272,760141,122Nov 27 11:36 AM
Gennadios AristipposPresident Softgel & Oral TechNov 25Sale52.5545,2562,378,20344,241Nov 27 11:36 AM
Grippo Michael JSVP, Strategy & Corp. Dev.Nov 22Sale52.0037619,55210,702Nov 26 05:07 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.